Canada · Delayed Price · Currency is CAD Lobe Sciences Statistics
Total Valuation
Lobe Sciences has a market cap or net worth of CAD 24.65 million. The enterprise value is 21.10 million.
| Market Cap | 24.65M |
| Enterprise Value | 21.10M |
Important Dates
The next estimated earnings date is Wednesday, December 30, 2026.
| Earnings Date | Dec 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lobe Sciences has 308.18 million shares outstanding. The number of shares has increased by 44.47% in one year.
| Current Share Class | 308.18M |
| Shares Outstanding | 308.18M |
| Shares Change (YoY) | +44.47% |
| Shares Change (QoQ) | +3.07% |
| Owned by Insiders (%) | 17.06% |
| Owned by Institutions (%) | n/a |
| Float | 108.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.70 |
| P/TBV Ratio | 13.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.38 |
| Quick Ratio | 2.24 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -214.20% and return on invested capital (ROIC) is -91.21%.
| Return on Equity (ROE) | -214.20% |
| Return on Assets (ROA) | -63.32% |
| Return on Invested Capital (ROIC) | -91.21% |
| Return on Capital Employed (ROCE) | -214.12% |
| Weighted Average Cost of Capital (WACC) | 3.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +77.78% in the last 52 weeks. The beta is -0.06, so Lobe Sciences's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | +77.78% |
| 50-Day Moving Average | 0.10 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 44.33 |
| Average Volume (20 Days) | 89,117 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.86M |
| Pretax Income | -7.06M |
| Net Income | -5.56M |
| EBITDA | n/a |
| EBIT | -6.86M |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 5.21 million in cash and 338,401 in debt, with a net cash position of 4.87 million or 0.02 per share.
| Cash & Cash Equivalents | 5.21M |
| Total Debt | 338,401 |
| Net Cash | 4.87M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 3.20M |
| Book Value Per Share | 0.01 |
| Working Capital | 3.20M |
Cash Flow
| Operating Cash Flow | -3.74M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | -11,373 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lobe Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.47% |
| Shareholder Yield | -44.47% |
| Earnings Yield | -22.54% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 10, 2022. It was a reverse split with a ratio of 0.166666667.
| Last Split Date | Jun 10, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.166666667 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |